Biotech startup Arrevus lands $800,000 in grants for sepsis and wound treatment

The Raleigh-based firm was awarded a $300,000 grant in support of its novel chaperone protein inhibitor, ARV-1502, for the treatment of sepsis. Separately, it received $500,000 from the Department of Defense’s U.S. Army Medical Research and Development Command for the same inhibitor to accelerate wound healing.

Read More